The safety of ceftolozane/tazobactam for the treatment of complicated urinary tract infections

References

• Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017 Oct;23(10):704–712. doi: 10.1016/j.cmi.2017.09.001
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Bassetti M, De Rosa FG, et al. Ceftolozane/Tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018 Apr;16(4):307–320. doi:10.1080/14787210.2018.1447381
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Gramatniece A, et al. New beta-Lactam-beta-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 Dec 16;34(1). doi:10.1128/CMR.00115-20
   Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Mussini C, et al. Clinical Efficacy of Ceftolozane-Tazobactam versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Oct 23;71(7):1799–1801. doi: 10.1093/cid/ciaa003
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bassetti M, Motyl M, et al. Ceftolozane/Tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. J Antimicrob Chemother. 2022 Aug 25;77(9):2522–2531. doi: 10.1093/jac/dkac184
   PubMed Web of Science ®Google Scholar
• Olney KB, Thomas JK, Johnson WM. Review of Novel beta-lactams and beta-lactam/beta-lactamase Inhibitor Combinations with Implications for Pediatric Use. Pharmacotherapy. 2023 Feb 24. doi: 10.1002/phar.2782
   Web of Science ®Google Scholar
• Moya B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother. 2010 Mar;54(3):1213–1217.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mills JC, Farrell DJ, et al. Mutation-driven beta-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014 Nov;58(11):6844–6850.
   PubMed Web of Science ®Google Scholar
• Moya B, Beceiro A, Cabot G, et al. Pan-beta-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother. 2012 Sep;56(9):4771–4778.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother. 2011 May;55(5):2390–2394.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Giacobbe DR, et al. Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: a Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infect Dis. 2020 May;7(5):ofaa139. doi: 10.1093/ofid/ofaa139
   PubMed Web of Science ®Google Scholar
• Cho JC, Fiorenza MA, SJ E. Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-Lactamase Inhibitor Combination. Pharmacotherapy. 2015 Jul;35(7):701–715. doi: 10.1002/phar.1609
   PubMed Web of Science ®Google Scholar
• Lizza BD, Betthauser KD, Ritchie DJ, et al. New Perspectives on Antimicrobial Agents: ceftolozane-Tazobactam. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0231820. doi: 10.1128/AAC.02318-20
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/Tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Wise R, Logan M, Cooper M, et al. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084.
   PubMed Web of Science ®Google Scholar
• Sime FB, Lassig-Smith M, Starr T, et al. Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01698-20
   Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/Tazobactam: a New Cephalosporin and beta-Lactamase Inhibitor Combination. Ann Pharmacother. 2015 Sep;49(9):1046–1056.
   PubMed Web of Science ®Google Scholar
• Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/Tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266–271. doi: 10.1016/j.ijantimicag.2015.05.003
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-Cuti)). Lancet. 2015 May 16;385(9981):1949–1956. doi: 10.1016/S0140-6736(14)62220-0
   PubMed Web of Science ®Google Scholar
• Huntington JA, Sakoulas G, Umeh O, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUtis) caused by levofloxacin-resistant pathogens: results from the ASPECT-Cuti trial. J Antimicrob Chemother. 2016 Jul;71(7):2014–2021.
   PubMed Web of Science ®Google Scholar
• Roilides E, Ashouri N, Bradley JS, et al. Safety and Efficacy of Ceftolozane/Tazobactam versus Meropenem in Neonates and Children with Complicated Urinary Tract Infection, Including Pyelonephritis: a Phase 2, Randomized Clinical Trial. Pediatr Infect Dis J. 2023 Apr 1;42(4):292–298. doi: 10.1097/INF.0000000000003832
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients with Complicated Urinary Tract Infections [last accessed 12 Mar 2023]. Available at: https://clinicaltrials.gov/ct2/show/study/NCT00921024
   Google Scholar
• Puzniak L, Dillon R, Palmer T, et al. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control. 2021 Apr 8;10(1):68. doi: 10.1186/s13756-021-00933-8
   PubMed Web of Science ®Google Scholar
• Jones BM, Huelfer K, Bland CM. Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting. Open Forum Infect Dis. 2020 Feb;7(2):ofaa014. doi: 10.1093/ofid/ofaa014
   PubMed Web of Science ®Google Scholar
• Bassetti M, Castaldo N, Cattelan A, et al. Ceftolozane/Tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019 Apr;53(4):408–415.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Jul 11;71(2):304–310. doi: 10.1093/cid/ciz816
   PubMed Web of Science ®Google Scholar
• Tran TT, Cabrera NL, Gonzales-Luna AJ, et al. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC Antimicrob Resist. 2023 Feb;5(1):dlac131.
   PubMedGoogle Scholar
• Diaz-Canestro M, Perianez L, Mulet X, et al. Ceftolozane/Tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2191–2200.
   PubMed Web of Science ®Google Scholar
• Escola-Verge L, Pigrau C, Los-Arcos I, et al. Ceftolozane/Tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Infection. 2018 Aug;46(4):461–468.
   PubMed Web of Science ®Google Scholar
• Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02291-19
   Web of Science ®Google Scholar
• Dinh A, Wyplosz B, Kerneis S, et al. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017 Jun;49(6):782–783.
   PubMed Web of Science ®Google Scholar
• Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: clinical Effectiveness and Evolution of Resistance. Clin Infect Dis. 2017 Jul 1;65(1):110–120. doi: 10.1093/cid/cix182
   PubMed Web of Science ®Google Scholar
• Balandin B, Ballesteros D, Ruiz de Luna R, et al. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Int J Antimicrob Agents. 2021 Mar;57(3):106270.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Dhami R, Baxter M, et al. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. J Glob Antimicrob Resist. 2021 Jun;25:346–350.
   PubMed Web of Science ®Google Scholar
• Pinilla-Rello A, Huarte-Lacunza R, Magallon-Martinez A, et al. Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multiresistant or extremely resistant Pseudomonas aeruginosa. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2021 Oct;34(5):441–449.
   PubMed Web of Science ®Google Scholar
• Almangour TA, Aljabri A, Al Musawa M, et al. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob Antimicrob Resist. 2022 Mar;28:288–294.
   PubMed Web of Science ®Google Scholar
• Ronda M, Perez-Recio S, Gonzalez Laguna M, et al. Ceftolozane/Tazobactam for difficult-to-treat Gram-negative infections: a real-world tertiary hospital experience. J Clin Pharm Ther. 2022 Jul;47(7):932–939.
   PubMed Web of Science ®Google Scholar
• Leitao IL, Mimoso Santos C, Andre P, et al. Ceftolozane/Tazobactam for the treatment of Pseudomonas aeruginosa infections: a multicenter case series analysis. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Jan 5. doi: 10.1016/j.eimce.2021.12.017
   Google Scholar
• Alosaimy S, Lagnf AM, Hobbs ALV, et al. Nephrotoxicity of Vancomycin in Combination with Beta-Lactam Agents: ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clin Infect Dis. 1455 [2023 Feb 8];76(3):e1444–e. doi: 10.1093/cid/ciac670
   Google Scholar
• Alqahtani SA, Kleiner DE, Ghabril M, et al. Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1328–1336.e2.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009 Jun;15(23):2817–2833. doi: 10.3748/wjg.15.2817
   PubMed Web of Science ®Google Scholar
• Shah T, Joslyn JA, Lai J. Ceftazidime induced liver injury. BMJ Case Rep. 2021 Dec;14(12):e246571. doi: 10.1136/bcr-2021-246571
   PubMedGoogle Scholar
• Zowawi HM, Harris PN, Roberts MJ, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015 Oct;12(10):570–584.
   PubMed Web of Science ®Google Scholar
• Murri R, Sacco E. What place does ceftolozane/tazobactam have in the treatment of complicated urinary-tract infections? Expert Opin Pharmacother. 2021 Aug;22(11):1377–1379. doi: 10.1080/14656566.2021.1915286
   PubMed Web of Science ®Google Scholar
• Bassetti M, Russo C, Vena A, et al. New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Curr Opin Infect Dis. 2021 Dec 1;34(6):701–709. doi: 10.1097/QCO.0000000000000757
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Castaldo N, et al. Role of new antibiotics in extended-spectrum beta-lactamase-, AmpC- infections. Curr Opin Infect Dis. 2021 Dec 1;34(6):748–755. doi: 10.1097/QCO.0000000000000789
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: when and How. Antibiotics (Basel). 2020 Feb 5;9(2):61. doi: 10.3390/antibiotics9020061
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Lagou S, Pontikis K, et al. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: for Whom, When, and How. Front Public Health. 2019;7:151. doi: 10.3389/fpubh.2019.00151
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Giani T, Bassetti M, et al. Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications. Clin Microbiol Infect. 2020 Jun;26(6):713–722.
   PubMed Web of Science ®Google Scholar